{"id":"W4402565813","doi":"10.1016/j.annonc.2024.08.2052","title":"1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Cohort; Urothelial carcinoma; Expanded access; Safety profile; Adverse effect; Immunotherapy; Cancer; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006208515,0.0002805237,0.000451056,0.0002393137,0.0003043953,0.0006984044,0.000276238,0.0003759549,0.004015664],"category_scores_gemma":[0.0007780857,0.0001530073,0.0008602013,0.0001798017,0.0002661709,0.0004238698,0.000214634,0.001001954,0.0006166],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008968128,"about_ca_system_score_gemma":0.0007957633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003292004,"about_ca_topic_score_gemma":0.007102707,"domain_scores_codex":[0.9997283,0.00007115379,0.00001542551,0.0000620689,0.00004383779,0.0000792951],"domain_scores_gemma":[0.9996585,0.00007216258,0.00006702561,0.00004115756,0.00002623007,0.0001350144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3477749,0.01219631,0.1752327,0.000572868,0.002647824,0.001021926,0.0003490323,0.003047162,0.1202695,0.0005402212,0.01191834,0.3244292],"study_design_scores_gemma":[0.04262021,0.2464401,0.6476978,0.0001463628,0.003298914,0.002180788,0.0002665293,0.003167709,0.02717816,0.0005239479,0.02640496,0.00007437095],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936135,0.001129717,0.0001372808,0.0002203028,0.00004148188,0.0001225235,0.001755167,0.00002985554,0.002950212],"genre_scores_gemma":[0.9947479,0.0004397152,0.0002099725,0.000190446,0.00004135833,0.00009853945,0.002443241,0.0000110606,0.001817798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004015664,"threshold_uncertainty_score":0.01343369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03841236257424397,"score_gpt":0.3611249404934512,"score_spread":0.3227125779192072,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}